RELAPSED/REFRACTORY MATURE B-NHL IN CHILDREN AND ADOLESCENTS

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2025-06-17 DOI:10.1002/hon.70093_31

A. Burke

{"title":"RELAPSED/REFRACTORY MATURE B-NHL IN CHILDREN AND ADOLESCENTS","authors":"A. Burke","doi":"10.1002/hon.70093_31","DOIUrl":null,"url":null,"abstract":"Relapsed and refractory (r/r) mature B-NHL in chidlren and adolescents represents an area of unmet cinical need due to the poor prognosis of these patients. Burkitt lymphoma and Diffuse Large B-cell lymphoma are the majority histologies.Mulitple new immuno-oncology therapies are available or being investigated in adult r/r mature B-NHL. The rarity of childhod and adolescent disease makes evaluation of all of these impossible and a more strategic approach is required.This lecture will explore the challenges of rational new drug development in this rare disease and highlight the current landscape with an emphasis on an international, transatlantic, academic-industry collaborative, fit-for-filing trial -Glo-BNHL (NCT05991388)Research funding declaration: CRUK, FKC, Multiple industry partners.Keywords: non-Hodgkin (Pediatric, Adolescent, and Young Adult); immunotherapy; ongoing trialsPotential sources of conflict of interest:A. BurkeOther remuneration: Institutional funding from Regeneron, ADCT Therapeutics and BMS for clinical trial","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"43 S3","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70093_31","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematological Oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hon.70093_31","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Relapsed and refractory (r/r) mature B-NHL in chidlren and adolescents represents an area of unmet cinical need due to the poor prognosis of these patients. Burkitt lymphoma and Diffuse Large B-cell lymphoma are the majority histologies.

Mulitple new immuno-oncology therapies are available or being investigated in adult r/r mature B-NHL. The rarity of childhod and adolescent disease makes evaluation of all of these impossible and a more strategic approach is required.

This lecture will explore the challenges of rational new drug development in this rare disease and highlight the current landscape with an emphasis on an international, transatlantic, academic-industry collaborative, fit-for-filing trial -Glo-BNHL (NCT05991388)

Research funding declaration: CRUK, FKC, Multiple industry partners.

Keywords: non-Hodgkin (Pediatric, Adolescent, and Young Adult); immunotherapy; ongoing trials

Potential sources of conflict of interest:

A. Burke

Other remuneration: Institutional funding from Regeneron, ADCT Therapeutics and BMS for clinical trial

查看原文本刊更多论文

儿童和青少年复发/难治性成熟b-nhl

儿童和青少年中复发和难治性（r/r）成熟B-NHL由于这些患者预后不良，代表了一个未满足临床需求的领域。伯基特淋巴瘤和弥漫性大b细胞淋巴瘤是主要的组织学类型。多种新的免疫肿瘤治疗方法可用于或正在研究成人或成熟B-NHL。由于儿童和青少年疾病罕见，因此不可能对所有这些疾病进行评估，因此需要采取更具战略性的办法。本讲座将探讨这种罕见疾病的合理新药开发面临的挑战，并强调当前的形势，重点是国际，跨大西洋，学术-行业合作，适合申请的试验- glol - bnhl （NCT05991388）研究经费声明：CRUK， FKC，多个行业合作伙伴。关键词：非霍奇金（儿童、青少年、青年）；免疫治疗;正在进行的试验潜在的利益冲突来源：其他报酬：来自Regeneron， ADCT Therapeutics和BMS的临床试验机构资助

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.